Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 0
Profit
Caution€ -4.8 million
▼ 191% vs 2024
Debts
Low€ 35,558
▼ 77% vs 2024
BIOTECH FONDS VLAANDEREN from Brussel, company number BE0454215168, closed financial year 2025 with a result of € -4.8 million after tax. For that financial year BIOTECH FONDS VLAANDEREN recorded a gross margin of € 0 and equity of € 24.5 million. Compared with financial year 2024, the result moved from € -1.6 million to € -4.8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 7, 2026.
What happened at BIOTECH FONDS VLAANDEREN?
What happened at BIOTECH FONDS VLAANDEREN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Particpatiemaatschappij Vlaanderen NV stepped down as director. NBB
- Elke Van De Walle stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 4.8 million. Source: NBB ↗
- Kenneth Wils stepped down as director. NBB
- Particpatiemaatschappij Vlaanderen NV became a director. NBB
- Elke Van De Walle became a director. NBB
- Kenneth Wils became a director. NBB
- New establishment in Brussel. KBO
In short
From € 1.4 million loss in 2021 to € 4.8 million loss in 2025.
Paid € 370 in corporate taxes since 2021.
Paid out € 25 million in dividends to the owners in total.
Pays suppliers within 40 days on average.
A new publication or filing at BIOTECH FONDS VLAANDEREN? We notify you, reason included.
Follow BIOTECH FONDS VLAANDERENNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 16.2% of Virovet, 16.1% of ReWind Therapeutics, 8.3% of reMYND, 6.5% of Biotalys and 3.8% of Augustine Therapeutics itself.
Directors
According to the 2025 annual accounts
Particpatiemaatschappij Vlaanderen NV
Director · represented by Michel Casselman
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE +141 more
since 2023 · until 2029
Elke Van De Walle
Director
since 2023 · until 2029
Kenneth Wils
Director
since 2023 · until 2026
Establishments
Establishment units
Physical locations of this company
Oude Graanmarkt 63
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 48 companies are registered at this address.
Moeve Chemicals Belgium
€ 1.3 million gross margin · 2025
Fietsersbond
€ 686,591 gross margin · 2025
Participatiemaatschappij Vlaanderen same network
€ 16.8 million revenue · 2025
SUSTAINABLE ENERGY VENTURES same network
PMV Beheer same network
+43 more
Details
- Company number
- 0454.215.168
- VAT number
- BE 0454.215.168
- Registered office
- Oude Graanmarkt 63, 1000 Brussel
- Names & denominations
- BIOTECH FONDS VLAANDEREN
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 1994
- Peppol
- Active · Active since 1 Jan 2001